

 <p>Anergy Testing</p>	Policy Number	TB-1004
	Effective Date (<i>original issue</i>)	May 16, 1995
	Revision Date (<i>most recent</i>)	June 26, 2008
	Subject Matter Expert (<i>title</i>)	Manager, Infectious Disease Intervention and Control Branch
	Approval Authority (<i>title</i>)	Manager, Infectious Disease Control Unit
	Signed by (<i>signature for hard copy; name for online</i>)	Susan C. Penfield, M.D.

1.0 Purpose

Persons with HIV (Human Immunodeficiency Virus) infection or other immune compromising conditions may not be able to react to the purified protein derivative (PPD) used in the tuberculin skin test (TST). In the past, other antigens were applied in a modified TST procedure in an attempt to assess whether a negative result of the TST was a false negative. This process was called anergy testing, which is no longer recommended by the Centers for Disease Control and Prevention (Anergy Skin Testing and Preventive Therapy for HIV-Infected Persons: Revised Recommendations, MMWR, September 5, 1997, Vol. 46. No. RR-15).

2.0 Policy

2.1 DSHS does not recommend anergy testing or supply the materials to perform this test.

3.0 Definitions

- 3.1 Anergy testing – a diagnostic procedure used to obtain information regarding the competence of the cellular immune system.
- 3.2 PPD – purified protein derivative is the antigen used in the tuberculin skin test for infection with *Mycobacterium tuberculosis*.
- 3.3 TST – the tuberculin skin test is a diagnostic procedure used to identify persons with infection with *Mycobacterium tuberculosis*.

4.0 Persons Affected

Employees of DSHS and local health departments
 Local and regional health department managers
 Physicians and nurses involved in the delivery of TB services

5.0 Responsibilities

6.0 Procedures

7.0 Revision History

Date	Action	Section
5/15/1995	New	
10/23/1996	Revised	
6/26/2008	Revised	